Results: A 60 year old man presented to the surgeons with an itchy, non-tender lump over his left temple and lethargy. PV was normal. Doppler ultrasound revealed a thrombosed temporal artery. Biopsy confirmed GCA.
Background: In giant cell arteritis (GCA) 10-15% patients have involvement of the aortic arch, the descending aorta and its' branches. The number of case reports of GCA with seropositive rheumatoid arthritis (SPRA) is small. Methods: We describe ''aortic syndrome'' GCA in a patient with SPRA on methotrexate. Results: A 71 year old lady with eight years of erosive SPRA on methotrexate 15 mg weekly complained of five months of night sweats, anorexia and depression. Further questioning revealed forearm pain and Raynauds without arthralgia, headache, scalp tenderness, jaw claudication or visual disturbance. Examination showed no synovitis or cutaneous vasculitis but radial and brachial artery pulsation were absent and subclavian bruits present. Blood pressure in the upper limbs was unrecordable. Temporal arteries were non-tender.
Blood tests showed PV 2.45, CRP 118, ALP 180, haemoglobin 8.8, platelets 655 (all relatively normal six months previously). MR angiography showed left vertebral, bilateral subclavian and axillary artery occlusion with collateral vessel formation and soft tissue swelling. CT angiography of the abdominal aorta demonstrated oedema and stenosis of the superior mesenteric and right renal artery. Temporal artery biopsy confirmed GCA.
Prednisolone was commenced and at two week review she was asymptomatic with PV 1.7 and CRP 1. Conclusion: Classic GCA developing in SPRA patients has been reported infrequently. Both conditions may share pathogenic mechanisms and are associated with HLA DR4. GCA affecting the aorta and large branches is uncommon and to our knowledge there are no reported cases (including rare involvement of the renal artery) in SPRA. Centocor, Inc. Malvern, PA, USA Background: Although GCA is responsive to glucocorticoids (GCS), therapy causes significant toxicity and often fails to induce sustained remission. Purpose: Assess safety and efficacy of infliximab (IFX) in patients (pts) with new onset GCA in a randomized, double-blind, placebo-controlled, multi-center, Phase II study. Methods: Eligibility: diagnosis of GCA (ACR criteria); GCA of 4 weeks (wks) duration; resolution of GCA features and normal ESR following treatment with 40-60 mg prednisone or prednisolone/day; remission for 1 wk prior to randomization. Exclusions: absence of infection, malignancies within 5 years, congestive heart failure and advanced disease of critical organs. Treatment randomization: 1:2 ratio, to receive infusions of placebo or IFX 5 mg/kg, respectively, at wks 0, 2, 6, 14, 22, 30, 38, 46 . All pts received GCS on a specified tapering schedule with starting dose between 40-60 mg/day. Visits: every 4 wks, through 54 wks; interim analyses at wk 22. Primary endpoints: proportion of relapse-free patients through wk 22 and safety (frequency and types of adverse events). Relapse definition: rise in ESR, normal to !40 mm; and one of following (i) 1 or more specified features of GCA; and (ii) any other features of GCA not attributable to any other cause and a concomitant increase in dose of GCS. Secondary endpoints included: (i) proportion of relapse-free patients at week 54; (ii) time to 1st relapse; and (iii) cumulative dose of GCS. Results: 44 pts were randomized (placebo, n ¼ 16, IFX, n ¼ 28) at 22 centers in 5 countries. Mean age in both groups (gps) was 71.0 years (range: 50-93). Baseline features between gps were comparable except for gender (placebo 31.3% males vs. IFX 14.3% males); fever (placebo 50.0% vs. IFX 17.9%) and visual impairment (placebo 31.3% vs. IFX 7.1%). More IFX-treated pts had positive temporal artery biopsies (66.7 placebo vs. IFX 92.3%). Efficacy was evaluated using cumulative data from 22 wks follow up. There were no differences between gps in regard to: (1) proportion of pts remaining relapse-free (50% placebo vs. 43% IFX, p ¼ 0.651), (2) cumulative doses of GCS therapy (placebo mean±SD ¼ 3117±971 mg vs. IFX ¼ 3051±770 mg, p ¼ NS) and (3) among pts who had 1st relapse, days to 1st relapse (placebo median ¼ 84.5, IFX median ¼ 96.5, p ¼ NS). There was 1 case of heart failure in an IFX-treated pt. Infections were infrequent and limited to upper respiratory tract (12.5% placebo vs. 14.3% IFX). Conclusions: In this elderly population of pts with newly diagnosed GCA, IFX 5 mg/kg every 8 weeks, was well-tolerated, but during 22 weeks of treatment did not reduce number of 1st relapses or cumulative GCS dosage.
iii18
Third International Conference on Giant Cell Arteritis and Polymyalgia Rheumatica Downloaded from https://academic.oup.com/rheumatology/article-abstract/44/suppl_3/iii18/1774071 by guest on 25 January 2019
